
Release date: 2026-03-24 16:52:08 Article From: Lucius Laos Recommended: 122
Patients should schedule regular follow-ups during treatment with Tepotinib and closely monitor any changes in their physical condition. If symptoms such as persistent difficulty breathing, jaundice, or severe edema occur, seek medical attention promptly.
While Tepotinib produces the intended therapeutic effects, it may also cause some adverse reactions. If you experience any of the following side effects while taking Tepotinib, seek medical attention immediately:
Anxiety, chest pain or tightness, cough, darkening of urine, difficulty or labored breathing, dizziness or lightheadedness, fainting, rapid heartbeat, fever or chills, general discomfort or fatigue, loss of appetite, muscle or bone pain, nausea or vomiting, sneezing, sore throat, abdominal pain, thickened bronchial secretions, shortness of breath, unusual tiredness or weakness, yellowing of the eyes or skin.
Tepotinib may cause some side effects that typically do not require medical intervention. If any of the following side effects persist, become bothersome, or if you have any questions, consult your healthcare provider:
Constipation, diarrhea.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Laos; pharmaceutical industry is relatively limited in scale, and domestic drug supply has long reli···【more】
Recommended:[list:visits]2026-26-06
MONDAY, June 15, 2026 — A study published online June 8 in Nature Medicine has found that apitegroma···【more】
Recommended:[list:visits]2026-24-06
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended:[list:visits]2026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:[list:visits]2025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:[list:visits]2025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:[list:visits]2025-08-12

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643